• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Projects
  • Funding
  • Research Data
  • Organizations
  • Researchers
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies.
 

Application of Perinatal Derivatives on Oncological Preclinical Models: A Review of Animal Studies.

Options
  • Details
BORIS DOI
10.48350/171954
Date of Publication
August 2, 2022
Publication Type
Article
Division/Institute

Universitätsklinik fü...

Contributor
Teixo, Ricardo
Pires, Ana Salomé
Pereira, Eurico
Serambeque, Beatriz
Marques, Inês Alexandra
Laranjo, Mafalda
Mojsilović, Slavko
Gramignoli, Roberto
Ponsaerts, Peter
Schoeberlein, Andreinaorcid-logo
Universitätsklinik für Frauenheilkunde
Department for BioMedical Research, Forschungsgruppe Pränatale Medizin
Botelho, Maria Filomena
Subject(s)

600 - Technology::610...

Series
International journal of molecular sciences
ISSN or ISBN (if monograph)
1422-0067
Publisher
MDPI
Language
English
Publisher DOI
10.3390/ijms23158570
PubMed ID
35955703
Uncontrolled Keywords

animal models cancer ...

Description
The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.
Handle
https://boris-portal.unibe.ch/handle/20.500.12422/86678
Show full item
File(s)
FileFile TypeFormatSizeLicensePublisher/Copright statementContent
ijms-23-08570.pdftextAdobe PDF1.1 MBAttribution (CC BY 4.0)publishedOpen
BORIS Portal
Bern Open Repository and Information System
Build: 27ad28 [15.10. 15:21]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo